Raju Mohan, Ventyx Biosciences CEO

Months af­ter a mam­moth raise, Ven­tyx Bio­sciences dips back in­to ven­ture well

Sev­er­al months af­ter emerg­ing from what CEO Ra­ju Mo­han called “qui­et mode” with a mam­moth $114 mil­lion raise, Ven­tyx Bio­sciences is now mak­ing its plans for the clin­ic loud and clear.

The Cal­i­for­nia-based im­mune mod­u­la­tion play­er kicked the week off with a $51 mil­lion Se­ries B, while al­so nam­ing some key hires ahead of its big clin­i­cal push.

The CMO slot is go­ing to Jörn Drap­pa, for­mer CMO at Viela Bio be­fore it was bought out by Hori­zon Ther­a­peu­tics ear­li­er this year. The As­traZeneca vet stayed on at Hori­zon for a while as ex­ec­u­tive VP of R&D be­fore mak­ing the jump to Ven­tyx.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.